实时血钾监测在血透患者中的成本-效用分析
本研究从美国医疗支付方视角,对血透患者使用实时血钾监测设备与常规护理进行成本-效用分析,采用微模拟模型,基线设备效果设为高钾血症事件减少25%。结果显示干预组10年内人均成本降低6381.21美元且QALY增加0.03,干预为优势策略;敏感性分析中99%模拟为优势。
要点
- 实时血钾监测在美国血透患者中10年内人均节省6381.21美元并增加0.03 QALY。
- 支付意愿阈值10万美元/QALY下,干预为优势策略,99%模拟中具成本效果。
- 盈亏平衡月成本为144.15美元/患者,成本效果阈值月成本为201.10美元/患者。
核心结论
- 从美国医疗支付方视角,血透患者使用实时血钾监测设备可能节省成本并改善结局。
研究设计与样本
- 成本-效用分析,采用微模拟模型,模拟美国血透患者,时间跨度10年,使用2022年美元。
主要发现
- 干预组10年内人均成本降低6381.21美元,QALY增加0.03,干预为优势策略。
- 成本效果阈值月成本为201.10美元/患者,盈亏平衡月成本为144.15美元/患者。
- 敏感性分析中,在10%、25%、50%效果估计下,99%模拟中干预为优势策略。
关键数值与推荐
- 基线设备效果设为高钾血症事件减少25%。
- 支付意愿阈值为每QALY 100,000美元。
- 成本效果阈值月成本201.10美元/患者,盈亏平衡月成本144.15美元/患者。
临床怎么用
- 对于美国血透患者,实时血钾监测可能作为节省成本并改善预后的干预措施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Patients with kidney failure requiring hemodialysis are at high risk for hyperkalemia between treatments, which is associated with increased cardiovascular morbidity and mortality. Early detection of hyperkalemic events may be useful to prevent adverse outcomes and their associated costs. We performed a cost-utility analysis comparing an intervention where a real-time potassium monitoring device is administered in patients on hemodialysis in comparison to usual care. METHODS: We developed a cost-utility model with microsimulation from the perspective of the United States health care payer. Primary outcomes included the monthly cost-effectiveness threshold cost and break-even cost per patient attributable to the intervention and the incremental cost-effectiveness ratio comparing the intervention to usual care. A 25% reduction in hyperkalemic events was applied as a baseline device effectiveness estimate. Concurrent first and second order microsimulations were performed using 10%, 25%, and 50% effectiveness estimates as sensitivity analyses. Results are presented over a 10-year time horizon in 2022 United States dollars and a willingness-to-pay threshold of $100,000 per quality-adjusted life year (QALY) was considered. RESULTS: Over 10 years, threshold and break-even analysis yielded maximum monthly costs of $201.10 and $144.15 per patient, respectively. The intervention was associated with reduced mean costs ($6381.21) and increased mean QALYs (0.03) per patient; therefore, was considered dominant. In sensitivity analysis, the intervention was dominant in 99% of simulations performed at all effectiveness rates. CONCLUSION: Implementing a real-time potassium monitoring device in patients on hemodialysis has the potential for cost savings and improved outcomes from the perspective of the United States health care payer.
引用
- Bamforth RJ, Ferguson TW, Tangri N, et al. Cost-Utility of Real-Time Potassium Monitoring in United States Patients Receiving Hemodialysis. Kidney Int Rep. 2024. PMID: 39534203. doi:10.1016/j.ekir.2024.08.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。